Patient P-03298
Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
9%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S05
- Day 29 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 29.
Primary contributors, last 14 days
- GI instability-23
- Nutritional resilience+20
- Inflammatory activity-13
- Treatment adherence-5
- Toxicity-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log7.1/10
improving · +0.3 vs previous 14 d
Stress level
Daily log3.9/10
improving · -0.3 vs previous 14 d
Pessimism score
Daily log4.9/10
improving · -0.3 vs previous 14 d
Sleep quality
Wearable63.5/100
improving · +4.3 vs previous 14 d
Libido
Daily log5.3/10
improving · +0.3 vs previous 14 d
HRV
Wearable57.1 ms
improving · +2.6 vs previous 14 d
Toxicity
Blood13.1/100
improving · -3.0 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 80 from the failing basin, 43 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +10.6
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -6.6 next day
Main detractors to watch
- Poor metabolizerhidden · steering -12.7
- Caffeineperturbation · steering -12
- Lactoseperturbation · steering -9.9
- Low microbial diversityhidden · steering -7.7
- Caffeinedetractor · GI +6.2 next day
- Lactosedetractor · GI +6 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.6supporter · 95%
- Caffeine+6.2detractor · 95%
- Lactose+6detractor · 95%
- Alcohol-3no signal · 35%
- Histamine load-0.7no signal · 15%
- Dietary fat load0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.9 · butyrate capacity 61/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 62 ms
- Sleep
- 7.5 h
- Steps
- 9,616
- Resting HR
- 73 bpm
Daily log: GI score 8, nutritional resilience 76, adherence 82.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03426 | 46% | S18 | BR-03 | improved | 27 |
| P-03235 | 41% | S13 | GI-04 | improved | 29 |
| P-03373 | 41% | S17 | BR-03 | improved | 34 |
| P-03013 | 40% | S07 | GI-04 | improved | 30 |
| P-03380 | 39% | S16 | AD-05 | improved | 34 |
| P-03424 | 37% | S12 | AD-05 | improved | 41 |
| P-03114 | 36% | S11 | DT-01 | improved | 48 |
| P-03215 | 36% | S16 | HY-01 | improved | 44 |
| P-03277 | 35% | S14 | BR-03 | improved | 41 |
| P-03233 | 34% | S19 | DT-01 | improved | 47 |
| P-03307 | 34% | S03 | ME-01 | improved | 17 |
| P-03442 | 34% | S11 | DT-01 | improved | 51 |